<DOC>
	<DOCNO>NCT00939562</DOCNO>
	<brief_summary>The purpose protocol study two different tablet formulation doxycycline bioequivalent .</brief_summary>
	<brief_title>Bioequivalence Between Two Tablet Formulations Of Doxycycline Carragenate</brief_title>
	<detailed_description />
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<criteria>Healthy male subject age 18 55 year . Body Mass Index ( BMI ) 18 30 kg/m2 . Evidence history clinically significant abnormality . Any condition possibly affect drug absorption . A positive urine drug screen .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Bioequivalence</keyword>
</DOC>